Major depressive disorder and taurine

Ketamine is being used in the treatment of major depressive disorder. Ketamine is a glutamate NMDA receptor antagonist. A ‘modulating ‘effect of ketamine on NMDA receptors has been stated as giving rise an antidepressant effect of ketamine in major depressive disorder.

Glutamate toxicity due to calcium influx through L-, P/Q-, N-type voltage-gated calcium channels and NMDA receptor calcium channels is inhibited by taurine with taurine having a neuroprotective effect. Addressing glutamatergic neurotransmission via taurine is much preferable to addressing glutamatergic neurotransmission via ketamine. Research points to supplemental taurine as reducing homocysteine levels (Ahn, 2009), reducing cholesterol levels in animals (Guo et al., 2017; Chen et al., 2012) having an anti-obesity effect, as being negatively associated with ischemic heart disease, as ameliorating diabetes and points to taurine deficiencies as resulting in premature aging. Research on rats points to ketamine resulting in dysregulations in the prefrontal cortex that persist even after ketamine withdrawal. Taurine supplemented alone is not a highly effective treatment for depression

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.